Table 4.
Relationship between adverse effects and age-adjusted antibody titers at 6 months after vaccination (n = 365).
| Adverse Effects | After the First Dose | After the Second Dose | ||
|---|---|---|---|---|
| Median (IQR) U/mL | p-Value | Median (IQR) U/mL | p-Value | |
| Systemic reactions | ||||
| Fever (≥37.0 °C) | 60 (−181 to 343)/−11 (−227to 256) | 0.187 | 57 (−201 to 359)/−25 (−229 to 207) | 0.065 |
| General fatigue * | 0 (−242 to 286)/1 (−223 to 263) | 0.853 | 35 (−217 to 328)/−117 (−241 to 174) | 0.015 |
| Headache * | −28 (−290 to 290)/8 (−214 to 263) | 0.278 | 30 (−240 to 336)/−20 (−224 to 254) | 0.425 |
| Muscle pain * | −4 (−256 to 248)/7 (−222 to 274) | 0.635 | 33 (−178 to 288)/−19 (−241 to 265) | 0.237 |
| Joint pain * | 142 (−71 to 461)/−7 (−240 to 256) | 0.023 | 54 (−92 to 339)/−58 (−264 to 244) | 0.001 |
| Nausea * | −56 (−339 to 314)/6 (−224 to 270) | 0.580 | −188 (−303 to −7)/14 (−221 to 283) | 0.013 |
| Diarrhea * | 695 (169 to 1036)/0 (−225 to 268) | 0.181 | −148 (−308 to 295)/1 (−224 to 271) | 0.294 |
| Local reactions | ||||
| Pain * | 9 (−240 to 274)/−55 (−186 to 144) | 0.441 | −9 (−317 to 341)/42 (−226 to 335) | 0.257 |
| Swelling * | 31 (−210 to 306)/−9 (−238 to 268) | 0.543 | −4 (−212 to 256)/3 (−232 to 273) | 0.785 |
| Induration * | 0 (−203 to 334)/6 (−233 to 268) | 0.697 | −49(−244 to 244)/11 (−226 to 280) | 0.476 |
| Itching * | 37 (−169 to 358)/−9 (−239 to 268) | 0.304 | 1 (−239 to 200)/0 (−224 to 281) | 0.735 |
| Acetaminophen use * | 78 (−224 to 446)/−8 (−233 to 251) | 0.191 | 46 (−208 to 334)/−58 (−246 to 209) | 0.019 |
* Yes/no are shown.